A team of scientists have bound gene editing CRISPR/Cas9 to nucleotide aptamers to selectively target and edit osteosarcoma cancer cells.
Browsing: Disease Area > Rare tumors
The largest genomics study of chordoma to date has discovered a gene mutation possessed by some patients which is a target for existing drugs known as PI3K inhibitors. Previously, these drugs have not been considered for chordoma.
Proper staging, early detection and accurate diagnosis all play a key role in successful treatment for cancer patients. Discover some of the treatment options for mesothelioma in this opinion piece.
Patients with rare cancers who are not able to receive standard treatment may be able to receive existing therapies designed for different cancers with the same genetic mutations, according to a novel study.
In this interview you can discover the current treatment options for mesothelioma as well as advancements that have been made in immunotherapy for this disease and what is being done to advance patient selection for this treatment modality.
In this article, the authors provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data.
In this patient perspective article, you can find out about the challenges associated with diagnosing mesothelioma and the promising role that biomarkers are playing.
Editor, Jade Parker recently spoke with world-renowned sarcoma expert, Robin L Jones. In this interview discover challenges in the diagnosis, treatment and clinical trials of sarcoma and other rare tumors.
Targeted sequencing focused on cancer-related genes provides comprehensive assessment of tumor mutational burden, with results comparable to whole-exome sequencing.
According to a new American Cancer Society Report, one in five cancer diagnoses in the United States is a rare cancer.